Inhibrx, Inc. (NASDAQ:INBX) Director Jon Faiz Kayyem Buys 69,686 Shares

Inhibrx, Inc. (NASDAQ:INBX) Director Jon Faiz Kayyem purchased 69,686 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The shares were purchased at an average cost of $14.23 per share, for a total transaction of $991,631.78. Following the completion of the transaction, the director now owns 51,093 shares in the company, valued at approximately $727,053.39. This represents a -374.80 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Inhibrx Price Performance

INBX stock opened at $14.08 on Friday. Inhibrx, Inc. has a 12-month low of $10.80 and a 12-month high of $18.95. The stock’s 50 day simple moving average is $15.61 and its 200 day simple moving average is $17.20.

Institutional Investors Weigh In On Inhibrx

Several institutional investors and hedge funds have recently made changes to their positions in INBX. Alpine Global Management LLC acquired a new stake in shares of Inhibrx during the 1st quarter valued at approximately $1,224,000. Price T Rowe Associates Inc. MD increased its position in Inhibrx by 8.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 14,812 shares of the company’s stock worth $518,000 after buying an additional 1,112 shares during the period. Finally, Black Maple Capital Management LP acquired a new stake in Inhibrx in the first quarter worth $555,000. 82.46% of the stock is owned by institutional investors and hedge funds.

Inhibrx Company Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.